

Dem Ausschuss ist das vorliegende Dokument
in nicht barrierefreier Form zugeleitet worden.

Why it is important to attach conditions to investments in regional production of health products

Statement on regional production & the African Vaccine Manufacturing Accelerator

25th meeting of the subcommittee on Global Health, Monday 10 June 2024

Aliénor Devalière, Senior Global Health Advocate, Wemos

Regional manufacturing

Target African Union

Produce & supply over 60% of Africa's vaccine requirements by 2040

At least 1.5 billion vaccine doses per year



Current initiatives targeting regional manufacturing

WHA Resolution 74.6



Medicines Patent Pool and Covid-19 Technology Access Pool



Partnerships for African Vaccine Manufacturing



mRNA vaccine technology transfer hub



Team Europe MAV+



Efforts towards regional manufacturing should:

- ▶ Improve access to medicines, vaccines and medical tools in Africa, by African manufacturers, for African populations.
- ▶ Enable low-and-middle-income countries to research, develop, manufacture and roll-out health products for and by themselves.
- ▶ Improve access, address specific health needs and make African countries less dependent on high-income countries.



Regional manufacturing

Should foster health equity,
sovereignty and self-reliance for the
African continent



Case study BioNTech Africa

- ▶ Background
- ▶ Key findings




Webinar

BioNTech Africa: in the region, but also for and by the region?

- Presentation of our **case study of regional production** of health products
- Reactions from experts

Wednesday 12 June 2024
15:00-16:30 CEST / CAT
Register via Zoom



Case study BioNTech Africa

Recommendations for EU governments

- ▶ Attach conditions to financial and technical support:
 - a) Align with public health priorities
 - b) Transfer of technology, knowledge and know-how to local manufacturers
 - c) Local, regional and continental entities in decision-making

Gavi's African Vaccine Manufacturing Accelerator

- ▶ New financial instrument to help catalyze the sustainable growth of vaccine manufacturing in Africa
- ▶ Designed to make up to US\$ 1 billion available over the next 10 years to support vaccine manufacturers in Africa scale up production and become sustainable in the long-term



Gavi's African Vaccine Manufacturing Accelerator

Eligibility

- ▶ Include African producers who hold ownership and who are involved in the decision-making process



Gavi's African Vaccine Manufacturing Accelerator

Financial incentives

- ▶ Target specifically local and regional manufacturers
- ▶ Go beyond narrow market interventions
- ▶ Invest in all steps of the vaccine manufacturing value chain



What can Members of Parliament do?

Key role to support health equity

- ▶ Attach conditions to financial and technical support
- ▶ Shape a favorable ecosystem along the vaccine manufacturing value chain
- ▶ Ensure greater transparency & public accountability



Thank you

wemos

Make health justice happen

Wemos

Plantage Middenlaan 14
1018 DD Amsterdam
+31 20 435 20 50

info@wemos.org
www.wemos.org

